Dense Breasts and Real Breast Cancer Risk

Here is a number that surprises most people: only 5 to 10 percent of breast cancers are hereditary (01:58). Everything else, the overwhelming majority, happens without a known genetic mutation or a dramatic family tree. Yet oncologist Eleonora Teplinsky, talking with OB-GYN Mary Claire Haver, says she routinely meets patients who skip mammograms for years because no one in their family has had the disease. "Is that a mistake?" Haver asks her. "One hundred percent," Teplinsky answers (01:41). The absence of family history feels like a shield. It is not one.

The real skill, Teplinsky argues, is reading family history correctly rather than ignoring or fearing it. A grandmother diagnosed at 85 tells a very different story than five women in one family diagnosed before 50.

"Grandma at 85 with breast cancer is very different than five women in your family under 50 get diagnosed with breast cancer." — Eleonora Teplinsky [01:10]

The second pattern, many relatives diagnosed young, points toward a hereditary cancer syndrome: a gene change passed down that raises risk across generations. The first pattern mostly reflects age, since cancer risk of almost any kind climbs as people get older. Confusing the two leads to two opposite mistakes: dismissing risk when a grandmother's age-related diagnosis gets lumped in with real genetic signal, or panicking over a single late-life case that shouldn't trigger alarm at all.

This is why Teplinsky wants breast cancer risk assessment to start at age 25 (02:45), using a free online tool like the Tyrer-Cuzick model, which factors in age at first period, family history on both the mother's and father's side, and breast density. The tool is imperfect. It misses some high-risk women and does not account for lifestyle. But it gives a number: a lifetime risk estimate. Cross 20 percent, and a woman is considered higher risk (03:45), which typically means a referral to a high-risk breast program, where mammogram alone may no longer be considered sufficient.

From there, the conversation about genetic testing opens up, and it is wider than most people assume. Testing isn't only about a mother's history. A father's side matters too, and so does a pattern that looks unrelated to breast cancer at first glance, like early-onset prostate cancer in men on either side of the family (06:01). BRCA is the mutation most people have heard of, but CHEK2, ATM, and PALB2 also raise risk, each with its own profile (05:12). Carrying a BRCA mutation specifically can mean up to an 80 percent lifetime risk of breast cancer (07:05), high enough that doctors typically raise the option of a risk-reducing mastectomy, though for women over 65 that calculation shifts and the benefit is less clear (07:12).

Teplinsky is careful to separate this evidence-based testing from a newer category of products marketed directly to consumers: blood tests like Galleri, which claim to detect a cancer signal from a vial of blood, and full-body MRI scans like Prenuvo, ordered without a doctor's referral. She is not dismissive. "I wanna know, right? I wanna know," she says of her own curiosity (08:43). But she is blunt about the limits: these tests can produce false positives and false negatives, they often miss early cancer confined to breast tissue, and a positive signal sends a patient hunting for the source through additional imaging and biopsies (08:59). Her bottom line is simple: these technologies should not replace proven, evidence-based screening like mammograms, colonoscopies, and Pap smears (09:40).

What Dense Breasts Actually Do

One exchange in the conversation corrects a widespread misunderstanding. Haver, herself a physician, admits she assumed dense breast tissue was a problem purely because it is harder to see through on a mammogram, hiding tumors that are there. Teplinsky's answer: "Both" (12:15). Dense tissue does make cancer harder to spot on a standard mammogram, and separately, it raises the actual risk of developing breast cancer, through a mechanism researchers still don't fully understand. About half of all women have dense breasts (12:28). They break into categories: category C, heterogeneously dense, covers roughly 40 percent of women and calls for an individualized conversation about added imaging. Category D, extremely dense, covers about 10 percent, and for those women Teplinsky says an MRI in addition to a mammogram is generally recommended (13:18).

Fear of the mammogram itself, specifically its radiation, also comes up. Teplinsky's comparison is worth remembering: the dose from a single mammogram equals roughly six to seven weeks of the background radiation a person absorbs just walking around outside (13:54). It is not zero. It is also not a reason to skip a test that catches cancer early.

The Previvor's Dilemma

The most consequential segment of the conversation concerns women who carry a high-risk mutation but have never had cancer, a group Teplinsky calls "previvors" (14:16). Consider a 38-year-old with a BRCA mutation who removes her ovaries to cut her ovarian cancer risk, while keeping her breast tissue intact. That surgery throws her into immediate surgical menopause, decades earlier than nature would have. For years, the reflexive advice to any woman with elevated breast cancer risk has been a blanket ban on estrogen. Teplinsky says that advice is outdated and keeping it in place has a real cost: some women delay or avoid the ovary-removing surgery that would protect them from ovarian cancer because they are afraid of the menopause that follows.

"Previvors can absolutely use hormone replacement therapy. I don't think women understand this." — Eleonora Teplinsky [15:04]

She points to a study led by researcher JoAnn Katsopoulos that followed more than 600 previvors who had their ovaries removed but kept their breast tissue (15:46). Women who took estrogen alone did not have a higher risk of breast cancer; in fact, their risk was lower than those who took no hormones at all. Women who took estrogen combined with a progestogen had equal risk, not elevated risk (16:08). That is a meaningfully different message than the one most patients have absorbed. It does not mean hormone therapy is risk-free or right for everyone. Some BRCA carriers also face early, observational signals of elevated uterine cancer risk, which is reviving conversations about whether hysterectomy belongs in the same surgical decision as ovary removal (18:21). But the study reframes what used to be treated as an automatic no into an actual conversation.

Skipping that conversation carries its own cost. Premature menopause before age 45 raises long-term risk for the heart, the brain, and the skeleton (19:15). Teplinsky's message to anyone who can't or chooses not to use hormones: it is never too late to revisit the option later, and hormones are only one part of a larger plan that should also include strength training for bone health, screening for heart risk, and attention to cognitive health (19:40).

There is a parallel correction buried later in the conversation, about genetic testing that comes back negative. A negative result does not automatically return a woman to average risk if her mother or sister had breast cancer and was never tested, or tested negative herself.

"It does not mean that your risk is back to that of the average woman." — Eleonora Teplinsky [21:35]

Family history, even without an identified mutation, still carries weight in the overall risk picture.

The episode's second half tracks what treatment does to the body once cancer is diagnosed, and here the throughline is the same: unglamorous, overlooked side effects deserve the same rigor as the headline treatment decisions. Chemotherapy-induced ovarian failure can drop lumbar spine bone density by 4 percent in just six months (22:00), and aromatase inhibitors, a class of hormone-blocking drugs, add another 2 percent of bone loss per year on top of that. Teplinsky's practical fix is a baseline bone density scan, ideally for anyone starting chemotherapy or endocrine therapy, not only those on hormone-blocking medication (23:36). Radiation carries its own quiet cardiac cost: a 2013 study found major coronary events rose about 7.5 percent after radiation for breast cancer, since the breast sits directly in front of the heart (27:36). Radiation oncologists now use a technique called the deep inspiratory breath hold, asking a patient to hold a deep breath during treatment so the heart shifts out of the radiation field (28:10).

What ties the whole conversation together is less a single statistic than a stance: that uncertainty should be met with better conversations, not blanket rules. A negative test is not a clean bill of health. A family history is not a sentence. A previvor is not required to live in menopause without options. The through-line, as Teplinsky puts it near the end, is that "everyone deserves a conversation" about their risk, their side effects, and their options (33:41). The data she cites throughout, on hereditary risk, on dense tissue, on hormone therapy after ovary removal, on bone density, on cardiac protection, exists specifically to make that conversation more honest than fear alone ever could.